Taken altogether, we propose that A4276 inhibits NAMPT at an optimal and balanced level allowing NAPRT-positive cells to survive through NAPRT-dependent NAD+ synthesis, unlike FK866, which causes excessive NAMPT disruption, thereby leading to the undesired death across several NAPRT-positive cancer cell lines with less efficient NAPRT/NAD+ flux. The gene discussed is NAPRT; the disease is cancer.